We Have Designed And Patented A Novel Molecular Scaffold That Allows Us To Inhibit Multiple Key Processescellular Signalingneeded By Cancer Cells To Proliferatemetastasizeand Growour Approach Challenges Industry Dogma Of One Drug One Target Which Results In Drugs That Work For Only A Short Period Of Time Before Resistance Occurs And Which Are Very Expensive Too Expensive To Be Added To Combinationsour Approach Of Dual Inhibition In One Drug Provides Simultaneous Inhibition Of Resistance Pathways Allowing A Drug To Be More Effective And Work Longer For The Patientour Approach Also Provides Huge Cost Savings2 Drugs In Oneto The Patient And Provides A Way To Get To More Complex Affordable Effective Cancer Drug Combinationslastlytoxicity From Off Target Effects Of Two Drugs Is Reduced By Using Our Dual Inhibitor Mechanism Providing Safer Treatments At Reduced Costs Our Dual Inhibitory Products Are In Various Stages Of Preclinical And Early Clinical Trial Studies
No conferences found for this company.
| Company Name | Signalrx Pharmaceuticals Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
